Neuropeptide S alleviates neuropathic pain in rats by activating lateral hypothalamic orexinergic circuits

Neuropathic pain represents a significant clinical challenge, often characterized by chronic, debilitating symptoms and limited effective treatment options. Current therapies frequently fall short in providing comprehensive relief, highlighting an urgent need for novel analgesic strategies. The orexinergic system, originating from the lateral hypothalamus (LH), is a crucial neuromodulatory pathway known to integrate physiological states with pain processing. Neuropeptide S (NPS) has emerged as a potential modulator of pain and affective states, with evidence suggesting its interaction with LH orexinergic neurons. Understanding this specific circuit could unlock new non-pharmacological approaches to pain management.

This preclinical animal study investigated the mechanism by which Neuropeptide S (NPS) modulates neuropathic pain in rats. Researchers administered NPS and assessed its antinociceptive effects. To elucidate the role of the orexinergic system, they utilized SB-334867, an orexin-1/2 receptor antagonist. This antagonist was infused into specific brain regions: the ventrolateral periaqueductal gray (vlPAG), and the nucleus accumbens and ventral tegmental area, which are known targets of orexinergic fibers. The primary endpoint was the modulation of NPS's antinociceptive effect by regional orexin-1/2 receptor blockade.

The study found that Neuropeptide S (NPS) exerted significant antinociceptive effects in the rat model of neuropathic pain. This analgesic action was critically dependent on the orexinergic system. Specifically, when an orexin-1/2 receptor antagonist, SB-334867, was infused directly into the ventrolateral periaqueductal gray (vlPAG), it completely blocked the antinociceptive effect of NPS. This indicates a central role for vlPAG orexin-1/2 receptors in NPS-mediated analgesia. > Infusion of SB-334867 into the nucleus accumbens and ventral tegmental area, key projection sites of orexinergic neurons, resulted in a partial blockade of NPS's antinociceptive effect. This suggests that while these regions contribute, the vlPAG plays a more dominant role in the observed analgesic pathway. These findings collectively position LH orexinergic neurons as a central node linking NPS signaling with pain modulation.